WY · State regulatory reference

Wyoming.

Restrictive

Wyoming permits telemedicine, but its Board of Pharmacy has a significant, documented enforcement record against unauthorized GLP-1 compounding. In 2024 the Board ordered City Drug of Cheyenne to cease all compounding after finding it was compounding semaglutide without proper sterile-compounding capability (March), then summarily suspended the pharmacy's license (September) over a compounded semaglutide product dispensed with a false label; the October 2024 settlement imposed a three-year stayed suspension, a multi-year compounding ban, fines plus disgorgement of the pharmacy's semaglutide profits, and a required sale of the business. Telehealth practice runs under the Medical Practice Act (Wyo. Stat. §§ 33-26-101 et seq.), and compounding under Board of Pharmacy Rules Chapter 22 adopts the USP chapters (795/797/800/825) by reference.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Wyoming Medical Board

https://wyomedboard.state.wy.us/ ↗

Pharmacy board

Wyoming Board of Pharmacy

https://pharmacyboard.wyo.gov/ ↗

TPC notes

Telehealth

A Wyoming-licensed physician may establish a relationship and prescribe non-controlled drugs via synchronous audio-video under the same standard of care as in person; controlled-substance prescribing requires a documented physician-patient relationship (Wyo. Stat. § 33-26-402(a)(xxxiii)).

Compounding

Board of Pharmacy Rules Chapter 22 adopts the USP compounding chapters (795/797/800/825) by reference; there is no distinctive statewide GLP-1 ban, but the Board has actively enforced against unauthorized semaglutide compounding — most visibly the 2024 City Drug summary suspension and settlement.

Sources